ATHA
- Athira Pharma, Inc.
()
Overview
Company Summary
Athira Pharma, Inc. (ATHA) is a biopharmaceutical company focused on developing innovative therapies to combat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company aims to address the significant unmet medical needs in these areas by developing new drugs that can potentially slow down or even reverse the progression of these diseases.
Athira Pharma is known for its unique approach, leveraging regenerative medicine to develop novel therapeutic candidates. The company's lead product candidate, ATH-1017, is a small molecule HGF/Met activator that aims to restore function in damaged brain cells. By stimulating the brain's regenerative capability and promoting the growth of new neurons, ATH-1017 has the potential to improve cognitive and functional abilities in Alzheimer's patients.
Athira Pharma's innovative treatment approach is based on scientific understanding of the molecular pathways involved in neurodegenerative diseases. The company conducts extensive research to unlock new insights into the mechanisms underlying these diseases and translate them into effective therapies.
In addition to drug development, Athira Pharma is actively engaged in clinical trials to evaluate the safety and efficacy of its investigational drugs. The company collaborates with renowned experts, research institutions, and organizations to advance its research and development efforts.
Overall, Athira Pharma's mission is to develop transformative treatments for neurodegenerative diseases, aiming to enhance the quality of life for millions of patients worldwide.